Abeona Therapeutics(ABEO)

Focus: Abeona Therapeutics is a public biotech company focused on gene transfer and cell therapies for rare genetic diseases, including Sanfilippo syndrome, epidermolysis bullosa, and mucopolysaccharidosis. With 1,001-5,000 employees and a Cleveland headquarters, the company operates at mid-cap biotech scale.

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

1001-5000

Open Jobs

About Abeona Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Abeona Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthStrong

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$6M

Pipeline & Clinical Trials

ABO-101

Mucopolysaccharidosis III-B

N/A

Clinical Trials (1)

NCT04655911A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101

N/A

Help build intelligence for Abeona Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Exposure to cutting-edge gene transfer and cell therapy modalities addressing severe rare genetic diseases with high unmet need
Balanced pipeline with 9 active trials including Phase 3 programs (EB-101, MSI-78) offering near-term visibility to clinical catalysts
Recent board reinforcement (Keith Goldan appointment) and fresh institutional investment ($3.25M from Aberdeen Group) signal management's commitment to stabilization

Watch Out For

Extremely tight cash position ($23M FY2025) against $34M annual R&D spend and -$63.7M net loss creates 6-9 month burn runway—restructuring or dilution risk is material
Zero current job openings and minimal recent hiring signal suggests frozen headcount; career advancement and internal mobility will be constrained
Pre-commercial stage with only $6M FY2025 revenue (likely milestone-driven) means no revenue-driven job security or commercial scaling opportunities

Generated by Claude from Abeona Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Collagen VII (COL7A1 gene transfer)

Recessive Dystrophic Epidermolysis Bullosa

Phase 1/2

NAGLU gene transfer

Mucopolysaccharidosis Type III B

Phase 1/2

ABO-102

MPS IIIA

Phase 1/2

LZRSE-Col7A1 Engineered Autologous Epidermal Sheets

Epidermolysis Bullosa Dystrophica

Phase 1/2

Clinical Trials (1)

NCT01263379Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa

Phase 1/2

rAAV9.CMV.hNAGLU

Mucopolysaccharidosis Type 3 B

Phase 1/2

Clinical Trials (1)

NCT03315182Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB

Phase 1/2

econazole

Onychomycosis

Phase 2

Clinical Trials (1)

NCT00385502A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail

Phase 2

UX111

MPS IIIA

Phase 2/3

EB-101

Recessive Dystrophic Epidermolysis Bullosa

Phase 3

Clinical Trials (3)

NCT05725018A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients

Phase 3

NCT04227106Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Phase 3

NCT05708677A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB

N/A

MSI-78

Diabetic Foot Ulcers

Phase 3

Clinical Trials (2)

NCT00563433MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

Phase 3

NCT00563394MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 9 clinical trials

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Financials (FY2025)

Revenue

$6M66%

R&D Spend

$34M(590%)11%

Net Income

-$64M

Cash

$23M

Source: SEC 10-K Filing

Abeona Therapeutics(ABEO)

About Abeona Therapeutics

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Abeona Therapeutics(10)

Open Jobs (0)

Financials (FY2025)